V
Vincent C. O. Njar
Researcher at University of Maryland, Baltimore
Publications - 154
Citations - 10648
Vincent C. O. Njar is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 42, co-authored 146 publications receiving 9790 citations. Previous affiliations of Vincent C. O. Njar include Saarland University & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
Observations on the Preparation of 2β-Hydroxy-19-oxoandrost-4-ene-3,7-dione (I). Synthesis of a 2β,19-Oxaandrost-4-ene-3,17-dione (II).
Journal ArticleDOI
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy.
TL;DR: The authors investigated the potential role of androgen receptor (AR) antagonism and the efficacy of cytochrome P450 17A1 (hereafter called CYP17) inhibitors in prostate cancer models.
Patent
Steroidal c- 17 benzoazoles
Angela Brodie,Vincent C. O. Njar +1 more
TL;DR: In this article, the synthesis of steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazole) and diazines is described.
Journal ArticleDOI
Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
TL;DR: Galeterone, 3β-(hydroxy)-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Gal, 1) and VNPP433-3β (4 and 5) are promising Phase 3 and Phase 1 drug candidates, respectively as discussed by the authors .
Journal ArticleDOI